This is a prospective clinical study to evaluate the safety and efficacy of R-CMOP in patients with newly diagnosed diffuse large B-cell lymphoma
Age ≥18 years;
Histologically confirmed newly diagnosed diffuse large B-cell lymphoma;
Patients must have been untreated, including chemotherapy, targeted therapy, immunotherapy, radiotherapy;
There must be at least one measurable lesion per the Lugano2014 criteria；
Primary central nervous system DLBCL, Primary testicular large B-cell lymphoma, Primary mediastinal (thymic) large B-cell lymphoma, Lymphomatoid granulomatosis, ALK-positive large B-cell lymphoma, Plasmablastic lymphoma, HHV8-positive DLBCL, Primary effusion lymphoma, Intravascular large B-cell lymphoma, B-cell lymphoma unclassifiable between DLBCL and classical Hodgkin lymphoma, T-cell/histiocyte-rich large B-cell lymphoma, and High-grade B-cell lymphoma；
transformed indolent lymphoma ;
Patients with active central nervous system involvement;
History of hematopoietic stem cell transplantation;